Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement. This agreement ...

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed oligonucleotide therapies from Creyon Bio. Oligonucleotides work as ...

TD Cowen analysts trimmed the price target for Eli Lilly and Company (NYSE:LLY) from $1,050 to $960, while reiterating a Buy ...

Persist AI announced a $12 million Series A funding round to support its new Cloud Lab platform, allowing companies to use its lab remotely for research and development.

We recently published a list of Jim Cramer Had These 21 Stocks on His Radar. In this article, we are going to take a look at ...

Eli Lilly and Purdue University are changing how ... areas of innovation in the pharmaceutical industry, including using AI-powered tools to augment traditional drug discovery methods ...

Eli Lilly and Company (NYSE:LLY) is expanding its neuroscience pipeline through the acquisition of SiteOne Therapeutics in a ...